Switch theme
Sign up to access all valuation multiples
Olympus is a medical device maker with a leading position in the endoscope market and a diversified global revenue stream. Originally founded in 1919 in Japan as a microscope and camera maker, Olympus has gradually pivoted into endoscopic and therapeutic solutions. As of March 2025, more than 60% of its revenue comes from endoscopic solutions. In addition, North America is the biggest revenue contributor by region, accounting for 38% of its total revenue.
1919
36.5K+
LTM Revenue $6.9B
LTM EBITDA $1.6B
$14.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Olympus has a last 12-month revenue (LTM) of $6.9B and a last 12-month EBITDA of $1.6B.
In the most recent fiscal year, Olympus achieved revenue of $6.4B and an EBITDA of $769M.
Olympus expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Olympus valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $6.9B | XXX | $6.4B | XXX | XXX | XXX |
| Gross Profit | $4.9B | XXX | $4.3B | XXX | XXX | XXX |
| Gross Margin | 71% | XXX | 67% | XXX | XXX | XXX |
| EBITDA | $1.6B | XXX | $769M | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 12% | XXX | XXX | XXX |
| EBIT | $1.1B | XXX | $302M | XXX | XXX | XXX |
| EBIT Margin | 16% | XXX | 5% | XXX | XXX | XXX |
| Net Profit | $795M | XXX | $1.7B | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 26% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Olympus's stock price is JPY 1855 (or $13).
Olympus has current market cap of JPY 2.09T (or $14.4B), and EV of JPY 2.07T (or $14.2B).
See Olympus trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $14.2B | $14.4B | XXX | XXX | XXX | XXX | $0.70 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Olympus has market cap of $14.4B and EV of $14.2B.
Olympus's trades at 2.2x EV/Revenue multiple, and 13.9x EV/EBITDA.
Equity research analysts estimate Olympus's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Olympus has a P/E ratio of 18.1x.
See valuation multiples for Olympus and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $14.4B | XXX | $14.4B | XXX | XXX | XXX |
| EV (current) | $14.2B | XXX | $14.2B | XXX | XXX | XXX |
| EV/Revenue | 2.1x | XXX | 2.2x | XXX | XXX | XXX |
| EV/EBITDA | 9.0x | XXX | 13.9x | XXX | XXX | XXX |
| EV/EBIT | 12.9x | XXX | 26.0x | XXX | XXX | XXX |
| EV/Gross Profit | 2.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 18.1x | XXX | 9.6x | XXX | XXX | XXX |
| EV/FCF | 17.5x | XXX | -212.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOlympus's last 12 month revenue growth is 1%
Olympus's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Olympus's rule of 40 is 18% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Olympus's rule of X is 27% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Olympus and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Growth | -1% | XXX | 28% | XXX | XXX | XXX |
| Rule of 40 | 18% | XXX | 18% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 27% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 62% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Olympus acquired XXX companies to date.
Last acquisition by Olympus was XXXXXXXX, XXXXX XXXXX XXXXXX . Olympus acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Olympus founded? | Olympus was founded in 1919. |
| Where is Olympus headquartered? | Olympus is headquartered in Japan. |
| How many employees does Olympus have? | As of today, Olympus has 36.5K+ employees. |
| Who is the CEO of Olympus? | Olympus's CEO is Mr. Stefan Kaufmann. |
| Is Olympus publicy listed? | Yes, Olympus is a public company listed on TKS. |
| What is the stock symbol of Olympus? | Olympus trades under 7733 ticker. |
| When did Olympus go public? | Olympus went public in 1949. |
| Who are competitors of Olympus? | Similar companies to Olympus include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Olympus? | Olympus's current market cap is $14.4B |
| What is the current revenue of Olympus? | Olympus's last 12 months revenue is $6.9B. |
| What is the current revenue growth of Olympus? | Olympus revenue growth (NTM/LTM) is 1%. |
| What is the current EV/Revenue multiple of Olympus? | Current revenue multiple of Olympus is 2.1x. |
| Is Olympus profitable? | Yes, Olympus is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Olympus? | Olympus's last 12 months EBITDA is $1.6B. |
| What is Olympus's EBITDA margin? | Olympus's last 12 months EBITDA margin is 23%. |
| What is the current EV/EBITDA multiple of Olympus? | Current EBITDA multiple of Olympus is 9.0x. |
| What is the current FCF of Olympus? | Olympus's last 12 months FCF is $812M. |
| What is Olympus's FCF margin? | Olympus's last 12 months FCF margin is 12%. |
| What is the current EV/FCF multiple of Olympus? | Current FCF multiple of Olympus is 17.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
